S-1/A: Picard Medical Files S-1/A for IPO, Reveals Significant Losses and Going Concern Doubts Amidst Artificial Heart Innovation Push

Picard Medical, Inc., developer of the FDA-approved SynCardia Total Artificial Heart, is seeking to raise $17 million in its initial public offering to fund operations and product development, despite a history of substantial operating losses and auditor-raised going concern doubts.

Summary

• Picard Medical, Inc. is a holding company that owns SynCardia Systems, LLC, which manufactures and sells the only U.S. FDA and Health Canada approved implantable total artificial heart (SynCardia TAH).
• The company is offering 4,250,000 shares of common stock in its initial public offering, with an estimated price range of $3.50 to $4.50 per share, aiming to raise approximately $15.4 million in net proceeds.
• Picard Medical has a history of significant net losses, reporting $(15.6) million in 2023 and $(21.1) million in 2024, and $(5.6) million for the three months ended March 31, 2025.
• Revenue decreased by 13% from $5.043 million in 2023 to $4.391 million in 2024, and significantly dropped by 69% from $1.980 million in Q1 2024 to $0.620 million in Q1 2025.
• The company's independent registered public accounting firm has included an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern.
• Proceeds from the IPO are intended to fund market expansion in China ($2.85 million), research and development for new products ($4.05 million), build sales and marketing capabilities ($0.5 million), and repay related party debt (up to $8.0 million).
• Picard Medical is developing a fully implantable total artificial heart called 'Emperor' with anticipated FDA approval in 2028, and next-generation portable and hospital drivers ('Freedom+' and 'Companion 3') expected by late 2026 and 2027, respectively.
• The company voluntarily withdrew its CE mark for the SynCardia TAH in Europe in July 2022 due to post-market surveillance deficiencies and plans to reapply for MDR CE mark in Q4 2025.
• There have been 104 reports of cannula tears in the SynCardia TAH, though zero Serious Adverse Events have been associated with these tears as of March 20, 2025; a design change is expected to be submitted to the FDA in Q3 2025.
• The company faces competition from alternative therapies like LVADs and other TAH developers such as Carmat SA (which filed for insolvency in France in July 2025) and BiVACOR, Inc. (early-stage clinical testing).
• Picard Medical relies on trade secrets for its proprietary material SPUS and manufacturing processes, as many original patents for the SynCardia TAH have expired.
• The company has significant customer concentrations, with Customer A accounting for 41% of revenue in 2024 and 49% in Q1 2025.
• Hunniwell Picard I, LLC will control a majority of the voting power post-IPO, making Picard Medical a 'controlled company' and allowing it to rely on certain NYSE corporate governance exemptions.

Sentiment

Score: 3

Explanation: The company faces severe financial challenges, including significant and increasing net losses, a substantial working capital deficit, and an auditor-raised going concern doubt. While it has a unique FDA-approved product and an ambitious pipeline, the current financial state and regulatory hurdles in Europe present considerable risks. The IPO is critical for survival, but the underlying financial performance is very weak.

Positives

• SynCardia TAH is the only U.S. FDA and Health Canada approved implantable total artificial heart, providing a significant market advantage.
• Over 2,100 SynCardia TAHs have been implanted in patients across 27 countries, demonstrating extensive clinical experience.
• The company has a robust product pipeline, including the fully implantable Emperor TAH and upgraded portable and hospital drivers (Freedom+, Companion 3, Unicorn).
• The SynCardia TAH implant procedures are eligible for DRG 001, the highest possible reimbursement under Medicare, with private insurers also providing coverage.
• Proprietary material Segmented Polyurethane Solution (SPUS) and manufacturing processes are considered a substantial competitive barrier.
• Successful completion of the latest MDSAP audit in November 2024 indicates strong quality management systems.
• The company is actively pursuing international market expansion, including a joint venture in China and efforts in India and the Middle East.

Negatives

• The company has a history of significant operating losses, with net losses of $21.1 million in 2024 and $5.6 million in Q1 2025.
• Revenue has declined, with a 13% decrease in 2024 compared to 2023, and a substantial 69% decrease in Q1 2025 compared to Q1 2024.
• The company has a significant working capital deficit of $(30.435) million as of March 31, 2025, and total liabilities of $40.620 million.
• The independent auditor has raised 'substantial doubt' about the company's ability to continue as a going concern.
• Many aspects of the SynCardia TAH are no longer protected by patents, increasing reliance on trade secrets and know-how.
• The company voluntarily withdrew its CE mark in Europe in July 2022 due to post-market surveillance deficiencies and is working to re-obtain it under new regulations.
• Reliance on sole-source suppliers (Bimba and Heitek Automation) for crucial driver components poses a supply chain risk, with no current agreement for PCA supply or drawings.
• The company has significant customer concentrations, making it vulnerable to changes in purchasing policies or loss of key customers.
• Outstanding related party loans and convertible notes, some of which are past due, indicate ongoing financial strain and dependence on related party financing.

Risks

• Inability to achieve and sustain profitability, leading to continued significant losses and adverse effects on financial condition.
• Challenges in manufacturing the SynCardia TAH on a timely basis consistent with quality standards due to highly specialized knowledge and operator skills.
• Reliance on specialized sole-source suppliers for critical components, which could lead to production delays or inability to meet demand if supply is disrupted.
• Unproven future demand for current and new products, and potential reluctance of physicians and hospitals to adopt the SynCardia TAH over existing alternatives like LVADs.
• Potential failure to successfully complete pre-clinical studies or clinical trials necessary for regulatory approvals of new products or expanded indications.
• Inadequate third-party payor coverage and reimbursement for products, which could negatively impact market acceptance and revenues.
• Adverse impacts from changes in U.S. and international trade policies, particularly with respect to China.
• Exposure to credit risk from accounts receivable, especially from foreign customers in economically unstable regions.
• Risks associated with currency fluctuations impacting results of operations.
• Potential product liability claims, product recalls, or field actions due to inherent risks in medical device design, manufacture, and use.
• Failure to protect intellectual property rights, including the expiration of patents and potential misappropriation of trade secrets.
• Extensive patent and intellectual property litigation in the medical device industry, which could be costly and divert management attention.
• Increased costs and demands on management as a result of complying with laws and regulations affecting public companies.
• Volatility in share price and potential for substantial losses for investors due to various market and company-specific factors.
• Significant dilution for stockholders upon conversion of certain outstanding securities, including preferred shares and convertible notes.
• Lack of an active trading market for common stock post-offering, or inability to sustain one.
• Potential for securities class action or derivative litigation, which could result in substantial costs and diversion of resources.
• Inability to implement and maintain effective internal control over financial reporting, leading to loss of investor confidence.
• Dependence on a single manufacturing location in Tucson, Arizona, which is subject to risks from disasters or disruptions.
• Potential for medical advances to provide better or less invasive alternatives, decreasing demand for total artificial hearts.
• Risks associated with international operations, including difficulties in enforcing IP, pricing pressure, and political/economic instability.
• Uncertainty regarding obtaining regulatory approvals in international markets (e.g., China, India, Middle East) on anticipated timelines or at all.

Future Outlook

Picard Medical aims to develop the world's first fully implantable SynCardia TAH (Emperor) as an alternative to heart transplantation, with FDA approval targeted for 2028. Near-term product developments include expanding the SynCardia TAH's indication for use from Bridge to Transplantation (BTT) to Bridge to Candidacy (BTC) and long-term use (2+ years), with FDA answers expected in Q2 2026 for the former. The company also anticipates FDA approval for its upgraded Freedom+ Driver by H2 2025 and next-generation Freedom and C2 Drivers by H2 2026 and H2 2027, respectively. International market expansion, particularly in China, India, and the Middle East, is a key strategic driver for future success.

Management Comments

• "Our future vision is to develop the world's first fully implantable SynCardia TAH as an alternative to heart transplantation for patients with biventricular heart failure in the U.S. and around the world."
• "For near term new product developments, we are committed to innovating our current driver technology, to expand the current indication for use of the SynCardia TAH from Bridge to Transplantation (BTT), to Bridge to Candidacy (BTC), and for long-term use of two years or more."
• "We believe that, based on our technology, intellectual property, know-how, and extensive human clinical experience, we have significant advantages over other companies developing other TAH products."
• "We expect to raise sufficient cash to fund our operations into 2025 based on our current business plan, and expectations and assumptions considering current macroeconomic conditions. However, these plans have not been finalized and there can be no assurance that we will be successful in raising any cash in connection with this offering."
• "We intend to aggressively protect, defend, and extend the intellectual property rights protecting our technology."
• "Our managers have identified significant issues with our regulatory compliance regime and are actively working to solve these issues."
• "We consider our relationship with our employees to be good."
• "As a sci-fi fan, [Richard Fang] believes in the ironman heart and has a vision that the SynCardia TAH will be a preferred alternative to heart transplant."

Industry Context

The medical device industry for heart failure treatment is highly competitive and subject to rapid technological change. Cardiovascular disease is the leading cause of death globally, with 56.2 million people suffering from heart failure worldwide. Heart transplantation is the treatment of choice for end-stage heart failure, but demand for donor hearts significantly exceeds supply (over 7,500 patients on the U.S. waitlist). This creates a market need for mechanical circulatory support devices like TAHs and LVADs. The global market for heart implants is substantial, with millions of heart failure patients in regions like the EU, India, China, and the Middle East. Picard Medical operates in a niche where its SynCardia TAH is the only FDA-approved total artificial heart in the U.S. and Canada, but it faces competition from LVADs (e.g., Abbott HeartMate 3) and other TAH developers like Carmat SA (which recently filed for insolvency) and BiVACOR, Inc. (early-stage).

Comparison to Industry Standards

• The SynCardia TAH is the only total artificial heart approved for commercial use in the United States and Canada, providing a significant regulatory advantage over competitors like Carmat's Aeson (EU approved, but facing insolvency) and BiVACOR (early-stage clinical testing, no market approval).
• With over 2,100 implants, SynCardia has significantly more human clinical experience than Carmat (108 implants as of July 2025) and BiVACOR (6 implants as of March 2025).
• SynCardia TAH (50cc and 70cc) has a smaller implant weight (250g) and volume (250-400ml) compared to Carmat's Aeson (900g, 750ml) and BiVACOR (650g, 400ml), allowing it to serve a broader patient population including women, children, and smaller-built men.
• The SynCardia TAH replaces both ventricles and all four heart valves, offering full circulatory support, unlike LVADs (e.g., Abbott HeartMate 3) which support only the left ventricle.
• SynCardia TAH patients can be discharged home with the portable Freedom Driver, a key advantage over temporary MCS devices like ECMO or axial flow LVADs which are for hospital use only and limited to short-term support (typically under two weeks).
• While LVADs like Abbott HeartMate 3 are reimbursed under DRG 001 (mean: $296,685), similar to SynCardia TAH, the SynCardia TAH offers a complete heart replacement solution for biventricular failure.
• The company's proprietary SPUS material and in-house manufacturing capabilities for heart ventricles are presented as a competitive moat, differentiating it from competitors who may rely more heavily on third-party component sourcing or different materials.

Management Changes

Corporate Governance

Legal Proceedings

• As of the date of this prospectus, the company is not a party to any material legal matters or claims.

Related Party Transactions

• As of March 31, 2025, the company has related party or affiliated loans totaling $6.5 million in current liabilities.
• Between June 2023 and March 2025, the company borrowed approximately $16.7 million from Fang Family Funds (affiliated with director Richard Fang) and Hunniwell, with various repayment terms and interest rates (some interest-free, some 6% per annum).
• A $7.0 million aggregated convertible note from Fang Family Funds, dated July 2, 2024, and related accrued interest, was donated to unrelated non-profit organizations (Nexus Science Foundation Inc. and Another Dimension Foundation) on November 12, 2024. These notes are currently past due.
• On July 1, 2025, the company amended a $250,000 related party working capital loan and issued new loans of $93,633 to Hunniwell and $187,190 to Daniel Teo (for severance) under the same terms as the Senior Secured Notes, with a maturity date extended to October 15, 2025.
• The company owes Medtronic approximately $492,000 in outstanding royalty payments as of December 31, 2024, for a license agreement that expired in July 2023, with Medtronic holding a security interest.
• The company has an ongoing commercial relationship with Bimba and Heitek Automation for crucial driver components, but lacks a formal agreement covering supply or access to drawings for the Piston Cylinder Assembly (PCA) and pneumatic manifold.
• In 2024, the company sent approximately $540,000 worth of inventory to SynCardia Medical (Beijing), Inc. for regulatory registration inspection and testing, which was recorded as general and administrative expense.

Stakeholder Impact

• **Shareholders**: Potential for significant dilution due to the IPO and conversion of preferred shares and convertible notes. Existing shareholders will experience immediate dilution. The company's ability to achieve profitability and sustain operations is critical for shareholder value.
• **Employees**: The company has over 75 employees and is increasing sales specialists. Continued operating losses and going concern doubts could impact job security and future compensation, though stock-based compensation is part of the incentive plan.
• **Customers (Hospitals/Medical Centers)**: Continued availability of SynCardia TAH and its drivers depends on the company's financial viability and regulatory compliance. Product issues like cannula tears, though not serious adverse events, require corrective action and communication. Reimbursement policies are critical for customer adoption.
• **Suppliers**: Reliance on sole-source suppliers for critical components (e.g., Bimba, Heitek Automation) means their stability and willingness to continue supply are vital for the company's operations. Unpaid royalties to Medtronic could strain that relationship.
• **Creditors**: The company has substantial debt, including related party loans and convertible notes, some of which are past due. The ability to repay these obligations depends on successful capital raises and achieving profitability.

Next Steps

• Complete the Initial Public Offering and list shares on the NYSE American under the symbol PMI.
• Utilize IPO net proceeds to fund market expansion in China, research and development activities for new products (Emperor, Unicorn, Freedom+, Companion 3), build sales and marketing capabilities, and repay debt.
• Continue efforts to address post-market surveillance deficiencies and reapply for MDR CE mark in Europe during 4Q25.
• Submit a design change to the FDA via a 180-Day PMA Supplement in Q3 2025 to address cannula tears.
• Await FDA answer in Q2 2026 regarding the 180-day PMA supplement to expand SynCardia TAH IFU to include Bridge to Candidacy and remove 'imminent death' requirement.
• Conduct acute animal studies for Emperor TAH design prototypes during the second half of 2025.
• Perform first-in-animal trials for the Emperor system in the second half of 2026.
• Complete regulatory testing for the Unicorn driver system in the second half of 2026, with FDA submission expected mid-2027.
• Seek FDA approvals for next-generation Freedom and C2 Drivers during the second halves of 2026 and 2027, respectively.
• Work with lenders to extend maturity dates for past-due convertible notes.
• Continue building resources and updating documentation to align with MDR requirements for CE mark reapplication.
• Pursue MD-15 import license and emergency use clearance strategies to enter the Indian market.
• Answer questions from the Saudi Food and Drug Authority (SFDA) regarding the Import and Distribution License application.
• Seek local distribution partners in the Middle East, Taiwan, the Gulf region, India, and Brazil.

Key Dates

Recommendation

Keywords

Total Artificial Heart, SynCardia TAH, Medical Device, Heart Failure, IPO, SEC Filing, FDA Approval, CE Mark, Bridge to Transplant, Emperor TAH, Freedom Driver, PMA Supplement, Going Concern, Biomedical Engineering, Cardiovascular Disease, Medical Technology, Clinical Trials, Intellectual Property, Corporate Governance, Related Party Transactions